Statistical and Bioanalytical Considerations for Establishing a Depletion Criterion for Specificity Testing During Immunogenicity Assessment of a Biotherapeutic
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 4
Abstract
The online version of this article (doi:10.1208/s12248-013-9523-1) contains supplementary material, which is available to authorized users.
Authors and Affiliations
R. O. Driscoll, L. Zhou, M. Moxness, D. Mytych, N. Chirmule, V. Jawa
Keywords
Related Articles
- EP ID EP681173
- DOI 10.1208/s12248-013-9523-1
- Views 50
- Downloads 0
Modeling, Simulation, and Translation Framework for the Preclinical Development of Monoclonal Antibodies
The industry-wide biopharmaceutical (i.e., biologic, biotherapeutic) pipeline has been growing at an astonishing rate over the last decade with the proportion of approved new biological entities to new chemical entities...
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
The monoclonal antibody market continues to witness an impressive rate of growth and has become the leading source of expansion in the biologic segment within the pharmaceutical industry. Currently marketed monoclonal an...
Using DTA and DTAARRAY Variables and Programming in WinNonlin ASCII Models to Streamline User-Defined Calculation and Data Analysis
The online version of this article (doi:10.1208/s12248-014-9711-7) contains supplementary material, which is available to authorized users.
In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms
Human pharmacokinetic in vivo studies are often presumed to serve as the “gold standard” to assess product bioequivalence (BE) of immediate-release (IR) solid oral dosage forms. However, when this general...
Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans
Pharmacokinetic–pharmacodynamic (PK–PD) modeling greatly enables quantitative implementation of the “learn and confirm” paradigm across different stages of drug discovery and development....